An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer.

Trial Profile

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 02 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016 as per ClinicalTrials.gov.
    • 02 Feb 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2016 as per ClinicalTrials.gov.
    • 09 Nov 2015 Results of pooled analysis from this and other two trials (n=110), presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top